Litcius/Paper detail

POS1042 EFFICACY AND SAFETY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE TYROSINE KINASE 2 (TYK2) INHIBITOR, COMPARED WITH PLACEBO AND APREMILAST IN MODERATE TO SEVERE PLAQUE PSORIASIS: RESULTS FROM THE PHASE 3 POETYK PSO-1 STUDY

April W. Armstrong, Melinda Gooderham, Richard B. Warren, Kim Papp, Bruce Strober, Diamant Thaçi, Elizabeth Colston, John Throup, S. Kundu, Subhashis Banerjee, Andrew Blauvelt

2021Annals of the Rheumatic Diseases27 citationsDOIOpen Access PDF

Topics & Concepts

ApremilastMedicinePlaceboPsoriasisPsoriatic arthritisInternal medicinePsoriasis Area and Severity IndexAdverse effectGastroenterologyArthritisDermatologyPathologyAlternative medicinePsoriasis: Treatment and PathogenesisCytokine Signaling Pathways and Interactions
POS1042 EFFICACY AND SAFETY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE TYROSINE KINASE 2 (TYK2) INHIBITOR, COMPARED WITH PLACEBO AND APREMILAST IN MODERATE TO SEVERE PLAQUE PSORIASIS: RESULTS FROM THE PHASE 3 POETYK PSO-1 STUDY | Litcius